Following the results of the present explorative study including tumour samples from 100 patients with epithelial ovarian cancer, we could identify VEGF-C as a potential molecular marker attributing the risk for retroperitoneal tumour progression to ovarian cancer patients. This evidence concerns the gene VEGFC and ovarian carcinoma.